Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
News about Teva Pharmaceutical Industries Limited (TEVA) focuses on its transformation into an innovative biopharmaceutical company, its generics and biosimilars franchise, and developments across neuroscience and immunology. Company announcements highlight progress on its Pivot to Growth strategy, including updates on branded medicines such as AUSTEDO, AJOVY and UZEDY, as well as late-stage pipeline assets.
Recent news includes clinical and regulatory milestones for AJOVY (fremanezumab-vfrm), where Phase 3 SPACE trial results in children and adolescents with episodic migraine were published in the New England Journal of Medicine. These data supported U.S. FDA approval for preventive treatment of episodic migraine in pediatric patients who meet specified criteria, adding to AJOVY’s existing indication in adults. News items provide details on trial design, efficacy outcomes, and safety profile.
Investors and followers of TEVA can also find updates on pipeline programs such as olanzapine extended-release injectable suspension (TEV-'749) for schizophrenia and the anti‑IL‑15 antibody TEV-'408 for vitiligo and celiac disease, including regulatory submissions and funding agreements. Teva’s news flow covers biosimilar approvals and collaborations, such as European Commission approvals for denosumab biosimilars PONLIMSI and DEGEVMA and the U.S. settlement and license agreement for AVT06, a proposed biosimilar to Eylea.
In addition, TEVA news features financial and capital markets events, including rating agency actions, amendments to credit facilities, quarterly earnings release dates, conference call schedules, and participation in major healthcare conferences. This mix of clinical, regulatory, strategic and financial updates makes the TEVA news page a central resource for tracking how Teva’s generics base, innovative pipeline and biosimilars portfolio contribute to its stated Pivot to Growth strategy. Users interested in TEVA stock can monitor this page for ongoing disclosures that may inform their understanding of the company’s operations and strategic direction.
Teva Pharmaceuticals has settled opioid-related claims with the Attorney General of West Virginia, agreeing to pay $75 million over 15 years and provide $27 million in the generic version of Narcan over 10 years. The settlement also includes $8 million for attorney fees. While this settlement advances efforts to address opioid addiction, it is not an admission of liability. Teva is negotiating a national settlement to further address ongoing litigation.
Teva Pharmaceuticals has released new data highlighting the efficacy and safety of AUSTEDO in postmenopausal women with tardive dyskinesia (TD) over a three-year open-label extension study. AUSTEDO showed significant improvements in motor symptoms, with 68% of patients experiencing notable improvements by Week 145. Additionally, the psychological, social, and physical impacts of TD were examined through surveys of patients and caregivers, revealing considerable negative effects on daily life. These findings will be presented at the 2022 American Psychiatric Association Annual Meeting in New Orleans.
Teva Pharmaceutical has received approval from the UK Medicines & Healthcare Regulatory Agency (MHRA) for its biosimilar Ongavia® (ranibizumab), targeting wet age-related macular degeneration (AMD) and other eye diseases. Ongavia® is the first ophthalmology biosimilar to be commercialized by Teva in Europe. The approval allows treatment for visual impairment-related conditions, potentially enhancing patient access to affordable therapies. Teva's partnership with Bioeq AG aims to extend Ongavia®'s commercialization throughout Europe.
Teva Pharmaceuticals announced four data presentations regarding AUSTEDO (deutetrabenazine) and TV-46000, presented at the American Psychiatric Association Annual Meeting from May 21-25, 2022. Key studies include long-term safety and efficacy of AUSTEDO for tardive dyskinesia, and a new copolymer technology for TV-46000 targeting schizophrenia. Teva will also host educational sessions on mental health's social determinants and the clinical benefits of long-acting injectables in schizophrenia treatment. The data reflects Teva's commitment to addressing mental health needs.
Teva Pharmaceuticals announced findings from a clinical study on SABA use among asthma patients, presented at the ATS 2022 Annual Meeting. The study revealed significant SABA overuse, with nearly one-third of patients making over 138 inhalations in 12 weeks. Key findings indicated that 89% of patients exceeded the consensus threshold for SABA use, suggesting a potential risk for asthma exacerbation. The ProAir Digihaler digital inhaler was highlighted as a tool to help healthcare providers make informed treatment decisions based on real-time patient data.
Teva Canada Limited has announced the public formulary coverage for AJOVY® (fremanezumab) in several provinces including Ontario, British Columbia, Nova Scotia, New Brunswick, and Newfoundland, enhancing accessibility for migraine patients across Canada. AJOVY® is indicated for adults with at least four migraine days monthly. This development follows similar coverage announcements in Alberta, Saskatchewan, and Québec. The increased availability of AJOVY® is expected to improve the quality of life for many Canadians suffering from migraines.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will present findings at the ATS 2022 Annual Meeting held from May 13-18, 2022, in San Francisco. These findings focus on the use of short-acting beta agonists (SABA) in asthma patients, utilizing data from the ProAir Digihaler. This analysis applies clinical usage thresholds from independent experts to objective patient data, marking the first such study of its kind. The research highlights the potential for digital inhalers to enhance asthma management and patient outcomes.
Summary not available.
Teva Pharmaceutical Industries reported Q1 2022 revenues of $3.7 billion, a decrease of 8% year-over-year, primarily due to lower sales in North America. GAAP diluted loss per share was $0.86, while non-GAAP diluted EPS was $0.55. The revenue outlook for 2022 has been revised lower to $15.4 - $16.0 billion amidst foreign exchange challenges and increased competition for COPAXONE, now expected at ~$750 million. Despite these challenges, Teva reaffirmed its adjusted EBITDA guidance of $4.7 - $5.0 billion and free cash flow of $1.9 - $2.2 billion.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Auspex Pharmaceuticals have settled litigation with Lupin concerning Lupin’s ANDA for a generic version of Teva's AUSTEDO (deutetrabenazine). Under the agreement, Lupin is granted a license to sell the generic product beginning in April 2033. AUSTEDO is the only FDA-approved treatment for tardive dyskinesia and chorea associated with Huntington’s disease. Teva's intellectual property related to AUSTEDO remains intact as they continue to litigate against Aurobindo over its ANDA for a similar product.
FAQ
What is the current stock price of Teva Pharm (TEVA)?
What is the market cap of Teva Pharm (TEVA)?
